RELEASE DETAILS

WALTHAM, Mass.--(BUSINESS WIRE)--Mar. 14, 2018-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced that it will present at the Oppenheimer 28^th Annual Healthcare Conference in New York, NY. Todd Bazemore, Chief Operating Officer at Kala Pharmaceuticals, will provide a corporate overview on Wednesday, March 21, 2018 at 10:55 AM ET.

To access a live webcast and subsequent archived recording of the presentation, please visit “Events” in the “Investors” section of the Kala website at http://kalarx.com/.

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, with an initial focus on the treatment of eye diseases. Kala has applied the MPP technology to a corticosteroid designed for ocular applications, resulting in two lead product candidates. The product candidates are INVELTYS^TM (KPI-121 1%) for the treatment of inflammation and pain following ocular surgery, for which an NDA has been accepted for review by the FDA, and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180314005262/en/

Source: Kala Pharmaceuticals, Inc.

Investors and Media:
MacDougall Biomedical Communications
Cammy Duong, 781-591-3443
cduong@macbiocom.com